Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E,  Bar-Ilan O, Mimrod D,8 and HayardenyL. J Neuroinflammation. 2017; 14: 172. Published online 2017 Aug 31. doi:  10.1186/s12974-017-0945-z

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
Stasiolek M, Linker RA, Hayardeny L, Bar Ilan O, Gold R. Immun Inflamm Dis. 2015 Jun;3(2):45-55. doi: 10.1002/iid3.42. Epub 2015 Mar 4. 

Laquinimod therapy in multiple sclerosis: a comprehensive review
Kolb-Sobieraj C, Gupta S, Weinstock-Guttman B. Neurol Ther. 2014 May 6;3(1):29-39. doi: 10.1007/s40120-014-0017-6. eCollection 2014. 

Defining a role for laquinimod in multiple sclerosis
Kieseier BC. Ther Adv Neurol Disord. 2014 Jul;7(4):195-205. doi: 10.1177/1756285614529615. 

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. Exp Neurol. 2014 Apr 13. pii: S0014-4886(14)00097-1. doi: 10.1016/j.expneurol.2014.04.002.  

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
Vollmer T. L,   Sorensen  P. S,  Selmaj K,  Zipp  F,  Havrdova  E, Cohen   J. A, Sasson  N, Gilgun-Sherki  Y,  Arnold  D. L. J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4. 

Oral laquinimod for MS—bringing the brain into focus
Brück W, Vollmer T. Nat Rev Neurol. 9, 664-665 (2013). doi: 10.1038/nrneurol.2013.234. 

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damageFilippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; on behalf of the ALLEGRO Study Group. J Neurol Neurosurg Psychiatry. 2013 Sep 12. doi: 10.1136/jnnp-2013-306132 

Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod
Lund BT, Kelland EE, Hayardeny L, Barilan O, Gilmore W, Weiner LP. J Neuroimmunol. 2013 Aug 3. pii: S0165-5728(13)00181-1 

Review of laquinimod and its therapeutic potential in multiple sclerosis
Thöne J, Gold R. Expert Opin Pharmacother. 2013 Dec;14(18):2545-52. doi: 10.1517/14656566.2013.848855. 

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Comi G, Jeffery D, Kappos L, Montalban X,  Boyko A, Rocca MA, M.D., Filippi M, for the ALLEGRO Study Group. N Engl J Med 2012;366:1000-9 

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis
Brück W, Zamvil SS. Expert Rev Clin Pharmacol. 2012 May;5(3):245-56. doi: 10.1586/ecp.12.12. 

Effect of Laquinimod on MRI-monitored disease activity in patients with RRMS: a multicenter, randomized, double-blind, placebo-controlled phase IIb study
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj KW, Sharrack B, Filippi M. The Lancet 2008, Volume 371, Issue 9630: 2085 - 2092. 

Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O & Nederman T. Neurology 64; 2005, 987-991.